Robert Sheehy

Introduction Interstitial lung disease (ILD) is a heterogenous group of over 200 lung conditions characterised by cellular inflammation and fibrosis of the pulmonary interstitium [1, 2]. ILD often follows a chronic course, resulting in significant symptom burden for patients, reducing life expectancy and culminating in substantial healthcare system costs [3].